This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Synageva BioPharma Corp (GEVA)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -95.45M -42.95M -25.31M 19.95M
Operating Gains/Losses 0.00 0.00 0.00 359.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 1.23M -388.00K 1.59M 7.00K
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -149.00K 1.07M 1.08M 0.00
(Decrease) Increase In Other Current Liabilities 7.29M 109.00K 1.85M -6.24M
(Increase) Decrease In Other Working Capital -4.59M 2.65M 2.74M 935.00K
Other Non-Cash Items 11.69M 5.32M 891.26K -17.64M
Net Cash From Continuing Operations -75.00M -30.94M -16.59M -2.49M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -75.00M -30.94M -16.59M -2.49M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 1.02M
Purchases of Property, Plant & Equipment -14.62M -394.00K -682.92K -781.00K
Acquisitions -2.50M 0.00 0.00 0.00
Purchases of Short-Term Investments -426.00M -195.36M 0.00 0.00
Other Cash from Investing Activities -1.94M -3.75M 50.11M 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -173.10M -199.50M 49.42M 238.00K
Issuance of Debt 0.00 0.00 12.50M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 286.35M 194.10M 186.18K 0.00
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 0.00 0.00 0.00
Net Cash From Financing Activities 286.35M 194.10M 12.69M 0.00
Effect of Exchange Rate Changes 9.00K -6.00K -4.05K 0.00
Net Change in Cash & Cash Equivalents 38.25M -36.35M 45.52M -2.26M
GEVA News

GEVA Synageva BioPharma Corp

Analysts Ratings for GEVA

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET GEVA ANALYST REPORT

Brokerage Partners

GEVA Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs